Cambrian Biopharma is a New York-based longevity biotech advancing multiple assets that each target a biological driver of aging. Led by CEO James Peyer and co‑founder and chairman Christian Angermayer, the company develops therapeutics intended to treat specific age-related diseases first and then be deployed as preventative medicines to lengthen healthspan and improve quality of life. Cambrian operates as a Distributed Development Company (DisCo) with a sourcing and development engine that enables identification of science, deep due diligence, deployment of capital and teams of drug development experts under the same model. It has 14 novel therapeutics in development across its majority-held pipeline companies. The company intends to use new funds to develop therapeutics to combat biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan. With the Series C, Cambrian has raised approximately $160 million since its founding in 2019.

Total raised

$100M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2021